Hikma Pharmaceuticals Plc - Company Profile
Powered by 
All the sales intelligence you need on Hikma Pharmaceuticals Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hikma Pharmaceuticals Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hikma Pharmaceuticals Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Hikma Pharmaceuticals Plc (Hikma) is a global pharmaceutical company focused on the development, manufacturing, and commercialization of a broad portfolio of generic medicines and in-licensed patented products. ikma Pharmaceuticals develops, manufactures and commercializes a wide range of products in the US, the Middle East and North Africa (MENA) and Europe.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focuses on the development and manufacture of high-quality medicines and the enhancement of its products. It is developing products for the evolving needs of patients and healthcare professionals. It is developing a portfolio of biosimilars for the US and MENA markets. The company offers its products in higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology. In FY2025, the company spent US$151 million on its research and development activities, which, as a percentage of revenue, stood at 4.5%. In FY2025, Hikma reported 139 regulatory filings, launched 84 new product launches and received approval for 99 products. The company has nine research and development center across the world.
Business Segments
Overview
Sells branded generics and in licensed new products in the MENA and other emerging markets. The segment has strong anti-infective franchise and increasing focus on cardiovascular, CNS and diabetes products. A few of the major products include Amoclan, Blopress, Prograf, Omnicef and Suprax. In FY2024, the segment launched 36 products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Sells non-injectable generic products in the US which include analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS and respiratory medicines. The company operates its Generics business through its US subsidiary, Hikma Pharmaceuticals USA Inc, formerly West-Ward Pharmaceuticals Corp. Its major products include amoxicillin, acetaminophen and caffeine, butalbital, buprenorphine, colchicine and fluticasone. Operates facilities in the US with a wide range of capabilities. In FY2024, the segment launched seven products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Sells specialized generic injectable products globally, with state-of-the-art manufacturing facilities in Europe and the US. Product portfolio includes controlled substances, anti-infectives, and cardiovascular and cancer products. A few of the products include fentanyl, neostigmine, glycopyrrolate, nicardipine and thiotepa. In FY2024, the segment launched 16 products in MENA, 53 in Europe and ROW, and 20 in North America. The pipeline of injectables focuses on new therapeutic entities, differentiated delivery forms and more complex products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the 503B compounding business, Arab Medical Containers, and the International Pharmaceuticals Research Centre, with ongoing investments in compounding capabilities and manufacturing.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer